Sanofi Income from Continuous Operations 2012-2026 | SNY
Sanofi annual/quarterly income from continuous operations history and growth rate from 2012 to 2026. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Sanofi income from continuous operations for the quarter ending March 31, 2026 was $1.866B, a 3.02% increase year-over-year.
- Sanofi income from continuous operations for the twelve months ending March 31, 2026 was $5.686B, a 13.55% decline year-over-year.
- Sanofi annual income from continuous operations for 2025 was $5.631B, a 6.31% decline from 2024.
- Sanofi annual income from continuous operations for 2024 was $6.01B, a 2.15% increase from 2023.
- Sanofi annual income from continuous operations for 2023 was $5.883B, a 34.18% decline from 2022.
|
Sanofi Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2025 | $5,631 |
| 2024 | $6,010 |
| 2023 | $5,883 |
| 2022 | $8,939 |
| 2021 | $7,429 |
| 2020 | $14,107 |
| 2019 | $3,291 |
| 2018 | $5,224 |
| 2017 | $4,422 |
| 2016 | $4,964 |
| 2015 | $5,010 |
| 2014 | $5,994 |
| 2013 | $5,147 |
| 2012 | $6,605 |
| 2011 | $11,533 |
|
Sanofi Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2026-03-31 | $1,866 |
| 2025-12-31 | $-889 |
| 2025-09-30 | $3,306 |
| 2025-06-30 | $1,403 |
| 2025-03-31 | $1,811 |
| 2024-12-31 | $436 |
| 2024-09-30 | $3,127 |
| 2024-06-30 | $1,203 |
| 2024-03-31 | $1,244 |
| 2023-12-31 | $-613 |
| 2023-09-30 | $2,762 |
| 2023-06-30 | $1,578 |
| 2023-03-31 | $2,156 |
| 2022-12-31 | $3,283 |
| 2022-09-30 | $2,094 |
| 2022-06-30 | $1,298 |
| 2022-03-31 | $2,263 |
| 2021-09-30 | $2,763 |
| 2021-06-30 | |
| 2021-03-31 | $1,902 |
| 2020-09-30 | $2,290 |
| 2020-03-31 | $1,870 |
| 2019-09-30 | $2,085 |
| 2019-03-31 | $1,303 |
| 2018-03-31 | $1,286 |
| 2017-12-31 | $48 |
| 2017-09-30 | $1,799 |
| 2017-06-30 | $1,181 |
| 2017-03-31 | $1,394 |
| 2016-12-31 | $842 |
| 2016-09-30 | $1,889 |
| 2016-06-30 | $1,115 |
| 2016-03-31 | $1,118 |
| 2015-09-30 | $1,837 |
| 2015-06-30 | $1,470 |
| 2014-06-30 | $1,103 |
| 2013-06-30 | $637 |
| 2012-06-30 | $1,569 |
| 2012-03-31 | $2,414 |
| 2011-12-31 | $1,887 |
| 2011-09-30 | $2,803 |
| 2011-06-30 | $1,453 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |